Exabis Library
Welcome to the e-CCO Library!
P672: A tertiary multicenter cohort of patients with chronic intestinal pseudo-obstruction and Crohn’s disease: a rare association with a high prevalence of monogenic disorders.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P672: Biologic therapy for Inflammatory Bowel Disease in Poland in 2020: nationwide data.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P672: Drug therapy and monitoring for inflammatory bowel diseases: preliminary data from a multi-centre investigation in Asia
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P672: Number needed to treat to achieve clinical response at week 8 along with response or remission at week 52 with ustekinumab treatment vs. placebo from the phase 3 UNITI Crohn’s disease studies, by population
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P672: Surgical and anti-TNFs combined therapy prevents Crohn's perianal fistula recurrence: a systematic review and meta-analysis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P672: Switching out of class or to another anti-TNF agent is the most effective strategy in IBD patients with immunogenicity against anti-TNF antibodies
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P673 Strategy of selecting anti-TNF agent in patients with Crohn’s disease: A multi-centre retrospective cohort study by the Osaka gut forum
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P673: Achievement of tight control based on serum C-reactive protein and albumin correlated with better outcomes in Japanese Crohn’s disease patients treated with biologics
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P673: Intra-abdominal collections in Crohn's disease: outcomes following anti-TNF therapy
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P673: Microbial diversity in newly diagnosed treatment naïve Inflammatory Bowel Disease patients
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P673: The safety of rapid versus standard infliximab infusions in children with inflammatory bowel disease: a multi-centre retrospective cohort study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P673: Trends in inflammatory bowel disease infections and vaccinations in the past four decades - a high-level text mining analysis of PubMed publications.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P673: Vedolizumab dose escalation as a way of recapturing response in patients with inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P674 Monitoring posologic change in adalimumab intensification dosing regimen from 40 mg every week to 80 mg every other week
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P674: Blood thiopurine level, anti-TNF drug level and body composition parameters in inflammatory bowel diseases patients: a cross-sectional study in a Hungarian IBD centre
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P674: Clinical characteristics and management of Crohn’s disease in patients with residual disease after surgery compared with curative surgery: Results from PRACTICROHN study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P674: Definition of a microbial signature as a predictor of anti-TNFα treatment response
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P674: Potential utility of therapeutic drug monitoring of adalimumab in predicting short-term mucosal healing and histologic remission in paediatric Crohn's disease patients
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P674: Predictors of response to biologics in Crohn's Diseases: A population-based study from the epi-IIRN
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P674: Ustekinumab is the preferred biological agent in IBD patients with hidradenitis suppurativa failing anti-TNF therapy : results from a real-life multicenter cohort
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM